

Ref: FOI/CAD/ID 3083

Please reply to:
 FOI Administrator
 Trust Management
 Maidstone Hospital
 Hermitage Lane
 Maidstone
 Kent
 ME16 9QQ
 Email: mtw-tr.foiadmin@nhs.net

12 January 2016

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biologics and Biosimilar.

1. Does your trust run a dedicated Gastroenterology infusion clinic for the treatment of patients with Infliximab [or Vedolizumab] If Yes, how frequently are they run?
2. Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below?

	<i>Rheumatology [Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis]</i>	<i>Dermatology [Psoriasis]</i>	<i>Hidradenitis suppurativa (sometimes known as acne inversa) L73.2</i>	<i>Gastroenterology [Crohns / Ulcerative Colitis]</i>
<i>Abatacept (Orencia)</i>				
<i>Adalimumab (Humira)</i>				
<i>Apremilast (Otezla)</i>				
<i>Certolizumab Pegol (Cimzia)</i>				
<i>Etanercept (Enbrel)</i>				
<i>Golimumab (Simponi)</i>				
<i>Infliximab (Remicade)</i>				
<i>Infliximab biosimilar (Inflectra)</i>				
<i>Infliximab biosimilar (Remsima)</i>				
<i>Rituximab</i>				

(MabThera)				
Secukinumab (Cosentyx)				
Tocilizumab (RoActemra)				
Tofacitinib [Xeljanz]				
Ustekinumab (Stelara)				
Vedolizumab (Entyvio)				

1. The Trust does not run a dedicated Gastroenterology infusion clinic.

2.

	Rheumatology [Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis]	Dermatology [Psoriasis]	Hidradenitis suppurativa (sometimes known as acne inversa) L73.2	Gastroenterology [Crohns / Ulcerative Colitis]
Abatacept (Orencia)	41	**	**	Not used
Adalimumab (Humira)	211	**	**	41
Apremilast (Otezla)	Not used	**	**	Not used
Certolizumab Pegol (Cimzia)	12	**	**	Not used
Etanercept (Enbrel)	86	**	**	1
Golimumab (Simponi)	83	**	**	Not used
Infliximab (Remicade)	54	**	**	122
Infliximab biosimilar (Inflectra)	*	**	**	*
Infliximab biosimilar (Remsima)	*	**	**	*
Rituximab (MabThera)	89	**	**	Not used
Secukinumab (Cosentyx)	Not used	**	**	Not used
Tocilizumab (RoActemra)	38	**	**	Not used
Tofacitinib [Xeljanz]	Not used	**	**	Not used
Ustekinumab (Stelara)	Not used	**	**	Not used
Vedolizumab (Entyvio)	Not used	**	**	2

--	--	--	--	--

* Current stats do not split

** Maidstone and Tunbridge Wells NHS Trust does not have a Dermatology service.

Data from June 2015 to November 2015 inclusive.